Pancreatic Cancer Research

ResearcherHammersmith HospitalActive in the last 2 years

Jonathan Krell

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9835-9227; OpenAlex author ID A5007279195. Sources: OpenAlex.

Their work

Papers
22 (first author 5, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 6 papers · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 22

  1. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03090-z↗
  2. Bile Microbiome Signatures Associated with Pancreatic Ductal Adenocarcinoma Compared to Benign Disease: A UK Pilot Study. Co-author DOI 10.3390/ijms242316888↗
  3. A Comprehensive Review of the Current and Future Role of the Microbiome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14041020↗
  4. The Role of Circular RNAs in Pancreatic Ductal Adenocarcinoma and Biliary-Tract Cancers. Co-author DOI 10.3390/cancers12113250↗
  5. Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-019-11752-2↗
  6. Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma? Co-author DOI 10.1080/14737159.2019.1622414↗
  7. TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-018-03962-x↗
  8. Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. Co-author DOI 10.18632/oncotarget.24873↗
  9. Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment. Co-author DOI 10.1080/14737159.2016.1175940↗
  10. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. First author DOI 10.1016/j.ejca.2015.04.006↗
  11. Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer. Co-author DOI 10.1001/jamasurg.2013.3643↗
  12. A microRNA meta-signature for pancreatic ductal adenocarcinoma. Co-author DOI 10.1586/14737159.2014.893192↗
  13. Serum miR-1290 as a marker of pancreatic cancer--letter. First author DOI 10.1158/1078-0432.ccr-13-1620↗
  14. Is the detection of circulating tumor cells in locally advanced pancreatic cancer a useful prognostic marker? Co-author DOI 10.1586/14737159.2013.845091↗
  15. Towards a clinical use of miRNAs in pancreatic cancer biopsies. Last author DOI 10.1586/erm.12.136↗
  16. Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer. Last author DOI 10.1586/erm.13.31↗
  17. Is there a 'margin' for error in pancreatic cancer surgery? Co-author DOI 10.2217/fon.12.175↗
  18. Circulating molecular markers in pancreatic cancer: ready for clinical use? Co-author DOI 10.2217/fon.12.187↗
  19. The role of miR-10b in metastatic pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.surg.2012.03.021↗
  20. Loss of miR-126 is crucial to pancreatic cancer progression. First author DOI 10.1586/era.12.67↗
  21. Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma? Co-author DOI 10.2217/pgs.12.73↗
  22. microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma. First author DOI 10.1586/era.11.184↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adam Enver Frampton · 22 shared papers, 2011–2024 · strength 1.49
  2. Elisa Giovannetti · 12 shared papers, 2013–2024 · strength 1.07
  3. Long R. Jiao · 16 shared papers, 2011–2024 · strength 0.95
  4. Justin Stebbing · 13 shared papers, 2011–2019 · strength 0.62
  5. Leandro Castellano · 12 shared papers, 2011–2019 · strength 0.58
  6. Daniel Liu · 4 shared papers, 2019–2024 · strength 0.52
  7. Tamara Gall · 8 shared papers, 2013–2015 · strength 0.35
  8. Shivan Sivakumar · 2 shared papers, 2023–2024 · strength 0.30
  9. Nabeel Merali · 2 shared papers, 2022–2023 · strength 0.28
  10. Nicola E. Annels · 2 shared papers, 2022–2023 · strength 0.28
  11. Tarak Agrebi Moumni Chouari · 2 shared papers, 2022–2023 · strength 0.28
  12. Geert Kazemier M · 3 shared papers, 2013–2024 · strength 0.27
  13. Niccola Funel · 3 shared papers, 2015–2019 · strength 0.18
  14. Mahrou Vahabi · 1 shared paper, 2024 · strength 0.16
  15. Benoît Immordino · 1 shared paper, 2024 · strength 0.16
  16. Annalisa Comandatore · 1 shared paper, 2024 · strength 0.16
  17. Jisce R. Puik · 1 shared paper, 2024 · strength 0.16
  18. Marc G. Besselink · 1 shared paper, 2024 · strength 0.16
  19. Luca Morelli · 1 shared paper, 2024 · strength 0.16
  20. Rutger‐Jan Swijnenburg · 1 shared paper, 2024 · strength 0.16
  21. Keith John Roberts · 1 shared paper, 2023 · strength 0.14
  22. Eirini G. Velliou · 1 shared paper, 2023 · strength 0.14
  23. Sladjana Zagorac · 2 shared papers, 2018–2019 · strength 0.14
  24. Sara Maria David Trabulo · 2 shared papers, 2018–2019 · strength 0.14
  25. Silvia Ottaviani · 2 shared papers, 2018–2019 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.